Ditchcarbon
  • Customers
  1. Organizations
  2. Gilead Sciences
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 10 days ago

Gilead Sciences

Company website

Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.

DitchCarbon Score

How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

61

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Gilead Sciences's score of 61 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.

78%

Let us know if this data was useful to you

Gilead Sciences's reported carbon emissions

In 2023, Gilead Sciences reported total greenhouse gas (GHG) emissions of approximately 1,179,798,000 kg CO2e. This figure includes 56,096,000 kg CO2e from Scope 1 (direct emissions), 22,339,000 kg CO2e from Scope 2 (indirect emissions from purchased electricity), and a significant 1,121,798,000 kg CO2e from Scope 3 emissions (indirect emissions from the value chain). Gilead has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 GHG emissions by 46% by 2030, using a 2019 baseline. Additionally, the company has committed to a 15% reduction in absolute Scope 3 emissions over the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Furthermore, Gilead aims to achieve carbon net-zero operational GHG emissions by 2030, encompassing both Scope 1 and 2 emissions. The company has made significant strides in its environmental strategy, with a near-term goal of reducing GHG emissions across Scope 1 and 2 by 25% by 2025 compared to a 2016 baseline. Overall, Gilead Sciences is actively working towards substantial emissions reductions and has established a framework for accountability and progress in its climate commitments.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20162017201820192020202120222023
Scope 1
44,754,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
36,813,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Gilead Sciences's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Gilead Sciences is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Gilead Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Ucb

BE
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated 26 minutes ago

Sai Life Sciences

IN
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Csl

AU
•
Pharmaceutical Preparation Manufacturing
Updated about 1 hour ago

Baxalta Incorporated

US
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250807.8
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy